Mangoceuticals (MGRX) EBT (2023 - 2026)

Mangoceuticals has disclosed EBT across 4 years of filings, most recently posting -$3.4 million for Q1 2026.

• EBT for Q1 2026 came in at -$3.4 million, up 29.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.2 million (down 71.81% YoY), and the FY2025 annual result was -$20.6 million, down 137.08% from the prior year.
• EBT came in at -$3.4 million for Q1 2026 at Mangoceuticals, down from -$2.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.6 million in Q3 2025.
• The 4-year median for EBT is -$2.6 million (2023), against an average of -$3.2 million.
• Across the five-year window, EBT sank 281.0% in 2025 and grew 29.68% in 2026, its largest moves.
• Mangoceuticals' EBT stood at -$2.6 million in 2023, then climbed by 24.12% to -$1.9 million in 2024, then tumbled by 42.12% to -$2.8 million in 2025, then slipped by 22.89% to -$3.4 million in 2026.
• The last three EBT figures came in at -$3.4 million (Q1 2026), -$2.8 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.